Effectiveness of swapping to ustekinumab after vedolizumab failure in patients with multi-refractory Crohn's disease



      Ustekinumab (UST) and vedolizumab (VDZ) are biologic therapies for moderate-to-severe Crohn's disease (CD) in patients who failed or had contraindication to anti-TNF treatment.


      To evaluate ustekinumab efficacy as third-line treatment after swapping from VDZ for failure.


      We conducted a monocentric, retrospective, observational study where CD patients were followed for 12 months from the beginning of UST therapy.
      We assessed clinical activity (HBI) and laboratory markers (CRP) at the initiation of UST therapy (T0) and after 2(T2), 6(T6) and 12(T12) months. Endoscopic activity was recorded at T0 and T12. We registered data regarding their clinical history and previous biologic treatments. Steroid-free clinical remission was defined as HBI ≤ 4 without need for steroids. Clinical response was defined as HBI reduction of at least three points or the suspension of steroids.


      27 CD patients treated with UST after VDZ failure had a minimum follow up of 12 months and were included. All patients had previously been treated with anti-TNF agents. After 12 months, steroid-free clinical remission was evident in 15 (55.5%) patients, 5 (18.5%) had clinical response, while 7 (26%) had suspended for failure or persisted on treatment after optimization.


      Ustekinumab should be considered as third-line biologic treatment in multi-refractory CD patients.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cholapranee A.
        • Hazlewood G.S.
        • Kaplan G.G.
        • Peyrin-Biroulet L.
        • Ananthakrishnan A.N
        Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
        Aliment Pharmacol Ther. 2017; 45: 1291-1302
        • Stidham R.W.
        • Lee T.C.H.
        • Higgins P.D.R.
        • et al.
        Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease.
        Aliment Pharmacol Ther. 2014; 39: 1349-1362
        • Ford A.C.
        • Sandborn W.J.
        • Khan K.J.
        • Hanauer S.B.
        • Talley N.J.
        • Moayyedi P
        Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.
        Am J Gastroenterol. 2011; 106: 644-659
        • Allez M.
        • Karmiris K.
        • Louis E.
        • et al.
        Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects.
        J Crohns Colitis. 2010; 4: 355-366
        • Fidder H.
        • Schnitzler F.
        • Ferrante M.
        • et al.
        Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
        Gut. 2009; 58: 501-508
        • Gisbert J.P.
        • Panés J
        Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.
        Am J Gastroenterol. 2009; 104: 760-767
        • Gisbert J.P.
        • Marín A.C.
        • McNicholl A.G.
        • Chaparro M
        Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
        Aliment Pharmacol Ther. 2015; 41: 613-623
        • Macdonald J.K.
        • Nguyen T.M.
        • Khanna R.
        • Timmer A
        Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
        Cochrane database Syst Rev. 2016; 11
        • Feagan B.G.
        • Sandborn W.J.
        • Gasink C.
        • et al.
        Ustekinumab as induction and maintenance therapy for Crohn's disease.
        N Engl J Med. 2016; 375: 1946-1960
        • Kassouri L.
        • Amiot A.
        • Kirchgesner J.
        • et al.
        The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab.
        Dig Liver Dis. 2020; 52: 1148-1155
        • Harvey R.F.
        • Bradshaw J.M
        A simple index of Crohn's-disease activity.
        Lancet. 1980; 315: 514
        • Bossuyt P.
        • Louis E.
        • Mary J.Y.
        • Vermeire S.
        • Bouhnik Y
        Defining endoscopic remission in ileocolonic Crohn's disease: let's start from scratch.
        J Crohns Colitis. 2018; 12: 1245-1248
        • Albshesh A.
        • Taylor J.
        • Savarino E.V
        • et al.
        Effectiveness of third-class biologic treatment in Crohn's disease: a multi-center retrospective cohort study.
        J Clin Med. 2021; 10: 2914
        • Gonczi L.
        • Szanto K.
        • Farkas K.
        • et al.
        Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab - a prospective, multicenter cohort from Hungary.
        Dig Liver Dis. 2022; 54: 207-213
        • Iborra M.
        • Beltrán B.
        • Fernández-Clotet A.
        • et al.
        Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry.
        Aliment Pharmacol Ther. 2020; 52: 1017-1030
        • Harris R.J.
        • McDonnell M.
        • Young D.
        • et al.
        Early real-world effectiveness of ustekinumab for Crohn's disease.
        Frontline Gastroenterol. 2019; 11: 111-116